TY - JOUR
AU1 - Lietz, Katherine
AB - Contemporary Reviews in Cardiovascular Medicine Donna Mancini, MD; Katherine Lietz, MD, PhD eart failure is a progressive disease that now affects 
5 substantial risk of death. The rising proportion of extremely H million patients in the United States. Recent estimates ill patients listed for HT renders the evaluation for MCS as suggest that between 5% and 10% of all patients with heart BTT an important part of HT evaluation. failure (HF) have advanced, or stage D, disease, which is According to the UNOS registry data, nearly 9000 HT associated with a very high mortality and very poor quality of candidates underwent MCS device implantation as BTT since 1 5 life. In the most advanced phase of HF, heart transplantation the new allocation system was introduced in 1999. This (HT) has been the only means of improving the quality of life constitutes more than one third of all listed adult HT and survival in these patients. With the advances in immu- candidates in the United States during this time period and nosuppression therapy, 1-year survival after cardiac trans- 75% of those initially listed as UNOS status 1. The wide- plantation approaches 90%, with 50% of patients surviving spread application of 
TI - Selection of Cardiac Transplantation Candidates in 2010
JF - Circulation
DO - 10.1161/CIRCULATIONAHA.109.858076
DA - 2010-07-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/selection-of-cardiac-transplantation-candidates-in-2010-7nWSmh9nc2
SP - 173
EP - 183
VL - 122
IS - 2
DP - DeepDyve
ER -